AZN•benzinga•
Tempest Weighs M&A, Analyst Sees A Broken Story Despite Phase 2 Liver Cancer Study Success
Summary
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 10, 2025 by benzinga